dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
Published 5 years ago • 2.3K plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
1:19
dr. robert on potential of dabrafenib/trametinib in melanoma brain metastases
-
1:46
dr. nathan on 5-year survival outcomes of combi-d and combi-v trials in braf v600-mutant melanoma
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
1:03
five-year os data for dabrafenib/trametinib combo in melanoma
-
1:33
dr. robert on next steps following the phase iii combi-v study in melanoma
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
2:11
dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
1:27
dr. weber on side effects of dabrafenib/trametinib in melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
0:44
dr. michael rotkowitz on dabrafenib and trametinib combination side effects
-
0:48
dr. michael rotkowitz on the dabrafenib plus trametinib combination for melanoma
-
2:37
dr. mark w. kieran on dabrafenib in pediatric patients with braf v600–mutant disease